SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
Sensys developed a non-invasive blood glucose monitor that used near infrared diffuse reflectance spectroscopy. The technology was designed to provide a painless method to collect data for proactive use in controlling diabetes.
Sensys Medical
Chandler, AZ
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.